We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Niox Group Plc | LSE:NIOX | London | Ordinary Share | GB00BJVD3B28 | ORD 0.08P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 61.00 | 108,833 | 12:36:46 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 60.00 | 61.00 | 64.00 | 60.40 | 64.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 36.8M | 9.5M | 0.0224 | 27.23 | 258.72M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 13:26:57 | O | 10,300 | 60.151 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 16/1/2025 | 15:46 | ALNC |  TRADING UPDATES: CAB Payments eyes cost cuts; Niox shakes up board |
| 16/1/2025 | 07:00 | UK RNS | Niox Group PLC Board Changes |
| 16/1/2025 | 07:00 | UK RNS | Niox Group PLC Full Year Trading Update |
| 06/1/2025 | 12:13 | UK RNS | Niox Group PLC Change of Registered Office |
| 20/12/2024 | 11:06 | UK RNS | Niox Group PLC Holding(s) in Company |
| 18/12/2024 | 18:15 | UK RNS | Niox Group PLC Director/PDMR Shareholding |
| 17/12/2024 | 09:15 | UK RNS | Niox Group PLC Holding(s) in Company |
| 05/12/2024 | 17:40 | UK RNS | Niox Group PLC Holding(s) in Company |
| 11/11/2024 | 17:05 | UK RNS | Niox Group PLC Holding(s) in Company |
| 28/10/2024 | 17:12 | UK RNS | Niox Group PLC PCA Dealing |
Niox (NIOX) Share Charts1 Year Niox Chart |
|
1 Month Niox Chart |
Intraday Niox Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 16/1/2025 | 17:05 | NIOX GROUP - expertise in asthma diagnosis and management | 248 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 13:26:58 | 60.15 | 10,300 | 6,195.55 | O |
| 12:36:46 | 61.00 | 200 | 122.00 | AT |
| 12:36:46 | 60.40 | 215 | 129.86 | AT |
| 12:36:46 | 60.40 | 542 | 327.37 | AT |
| 12:36:34 | 60.49 | 13,290 | 8,039.12 | O |
| Top Posts |
|---|
Posted at 28/1/2025 08:20 by Niox Daily Update Niox Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker NIOX. The last closing price for Niox was 61p.Niox currently has 424,127,241 shares in issue. The market capitalisation of Niox is £258,717,617. Niox has a price to earnings ratio (PE ratio) of 27.23. This morning NIOX shares opened at 64p |
Posted at 16/1/2025 17:05 by eezymunny Never researched this one until today. Looks a nice little company but there seems to be plenty of competition. Anything special about the NIOX kit that all the others can't do? Gross margin most recently 72%. Is that defendable?Just Google "feno testing equipment" to see some competitors. |
Posted at 06/1/2025 23:24 by earwacks I thought so too. Not sure why Griffith has been so persistently selling down. Presumably has better opportunities. I know he has been building a stake in Dlar this year. I switched to Renx, Vrci and topped up in Cog, all up over 30 percent over Christmas period. I think Niox is ok but the vaccination and Griffiths sell off spooked me a bit, but mostly I see better opportunities in Renx particularly and had no spare cash. Niox should be ok with the updated FeNox and home kit development, but they are just paying back the cash they make to shareholders for the two years with no real goal for development in any other area. Could get bought out, but quite a risk as all their eggs in one basket. Unlikely there will be a total cure for asthma for a while ye, so the dividends should flow, but not sure how strong growth will be. How much of the market will the home kit test be and will it impact on the the surgery test? I don’t know really. Has far to big a holding and decided I needed to get much more diversified from five holdings 60 percent of which was in Niox. Obviously still plenty of demand for their shares as had no problem selling.gl |
Posted at 02/12/2024 19:09 by edwardt Surely that is not good for niox! |
Posted at 08/11/2024 15:27 by earwacks Amazing 1 automatic share trade @63.2 drops the price several hundred thousand, but no amount of buys of 250,000 moves the Sp a jot |
Posted at 23/10/2024 10:45 by earwacks Clearly there has been some selling yesterday but quite a few buying back in presumably re-investing winnings. I fully intend to do the same. Just a question of timing. We won’t get another TU update till late January. A lot depends on what mr Griffiths and co do. I think there will be plenty of appetite even if they do offload a few more. Singer have reinstated their buy recommendation even though not increasing revenue upgrade but they have increased the EBITDA ad raised share price target siting further payouts as they accumulate cash again. 5 brokers have targets in a range of 69-91p. The good thing is some kind of dividend or payout is pretty certain plus we don’t yet know how the new upgraded version will sell. They are going to push sales and hoping to grow substantially in the USA. Then there will hopefully be further updates on home test developments. I’m not entirely convinced by Mills suggesting most of the money has been made here. It has more than doubled from its low, but I can see a buyout price in excess of £1.00 per share, although unfortunately probably not Astra (they could buy this with a days revenue possibly). Wallet investor have a 5 year target of £2.67!Maybe many stocks can outstrip that. In the meantime it is definitely a core holding and nice little earner with a 5 percent annual return. GL |
Posted at 17/10/2024 06:40 by earwacks Payment by October 22. Slight over application to the tender by around 4 million shares. I would imagine mostly fund managers. Looks like everyone took part in tender including directors and major shareholders. Now will we see a rush to exit. May provide an excellent opportunity to top up. I suppose as Astra Zenica took part maybe rules them out for possible takeover. I think their holding is mostly a hangover from the Circassia debacle.Mugs game trying to predict! Ultimately this looks a great company now and for the future. Much appreciate the buyback at a premium |
Posted at 08/10/2024 15:06 by earwacks O good Jimmy. I see the cut off date is actually oct 15th. I think most people have the same plan to reinvest at a lower price. Be interesting to see how that works out. I will probably keep the cash for a bit to see how the share price settles. Don’t think It needs to be rushed reinvesting as the home test is still a way off production, but a possible takeout is always on the cards. In the meantime we keep getting a hefty wedge of the increasing cash generation |
Posted at 21/7/2024 18:37 by badday Gets a mention on the Paul Scott podcast ( always worth a listen)Interesting that he says Christopher Mills due to do Paul Hills (Vox Markets) interview next week. Christopher Mills was thinking it was fully valued for now, but growing into that value. Might have something to say Anyway Paul Scott comments below: “Another interesting company that I've gone green on, which might surprise you, because it's not my usual sort of value share, is a thing called NIOX, N-I-O-X. That put a trading update out. I had another refresh of the figures. It's quite pricey, but it does something to do with asthma products. And look at the shareholder list on that. You've got Harwood, you've got AstraZeneca, and you've got somebody else who owned about a third of the shares, who were all big name major investors. So the way I look at it is, they've done the due diligence for us, haven't they? And they obviously think it's good, although... Oh, that was it, Rathbones had bought some shares from the other two big shareholders. Richard Griffith, I think, was the other one who's got a big position there. He doesn't get everything right, nobody does, but he's certainly a smart cookie. Anyway, so Niox, I think, is worth you having a look at.” From Small Caps Podcast with Paul Scott: Episode 29 (20 July 2024) - UK Small/Mid Caps with Paul Scott, 20 Jul 2024 This material may be protected by copyright. |
Posted at 27/4/2024 14:19 by earwacks Astra dissolved their partnership with Circassia over Tudorza and Duklar inhaler for COPD.Astra retained commercial rights in consideration of 150 million dollar debt and retained 18 percent of Circassia, now Niox. Astra have since offloaded this product. Not sure how successful it has been. Probably nothing like the FeNo tester. What Niox have is the development of the best Asthma diagnostic device and 600 million tax credit for the Circassia debacle. Meaning they will never pay tax on their very cash generative device. The tax credit is also transferable which makes it an added asset to their £270 million market cap. The directors are probably nearing retirement. They have built a highly profitable business from the wreckage of Circassia, making it a market leader in its field, but still only tapping 5 percent of possible world market. Added to that they are developing a domestic kit, which if successful will probably appeal to a us pharma giant, not necessarily just Astra, who as you say may not be interested as it is Gsk that have recently purchased a company that have developed an asthma drug. Potential for Niox is pretty big and are at an interesting stage where they might need some serious gearing up to reach potential global markets, whilst having converted themselves into a growing cash machine. Although expensive on last years results I don’t think forecasters have quite got their head around the potential of Niox yet |
Posted at 23/2/2024 18:18 by earwacks I think it’s held up well considering The uk is the worst performing market in the world and many British companies make most of their money in global business.This is a recent high for NIOX. It is similar to share price movement last year between update and actual results. News on dividend and cash position should help re establish the share price Then of course there is the expectant takeover by AZN Why else would they hold 16 percent of the. Company? Gl all |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
